<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770939</url>
  </required_header>
  <id_info>
    <org_study_id>2007-001</org_study_id>
    <nct_id>NCT00770939</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers</brief_title>
  <official_title>A Cohort Study to Evaluate the Effect of Vivostat Platelet Rich Fibrin on Diabetic Foot Ulcers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivostat</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vivostat</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic foot ulcers are a challenge to health care professionals because there are only few&#xD;
      effective topical therapeutic interventions.&#xD;
&#xD;
      Growth factor treatment has shown to be beneficial for healing of diabetic foot ulcers in&#xD;
      conjunction with extensive surgical debridement. Autologues platelet releasate which contains&#xD;
      platelet derived growth factor appears to be more effective than standard therapy in case&#xD;
      studies.&#xD;
&#xD;
      This protocol will evaluate the healing effect of Vivostat PRF treatment of non-eschemic foot&#xD;
      ulcers to identify responders and to enable sample size calculation for a subsequent pivotal&#xD;
      trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of completely healed ulcers after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with a 50% reduction of wound area after 4 and 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Granulation rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vivostat PRF</intervention_name>
    <description>Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 4 weeks history (with wound area measurements) within a wound care&#xD;
             institution before the first visit (week -3). In case of referral the patient history&#xD;
             must be documented&#xD;
&#xD;
          -  All patients must complete a 3 week screening period i.e. they will be interviewed and&#xD;
             accessed at the first meeting. During the 3 week period patient compliance will be&#xD;
             monitored.&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Type I or Type II Diabetes Mellitus&#xD;
&#xD;
          -  Ulcer at or below the ankle which has been present for at least 4 weeks, and has&#xD;
             received best practice care&#xD;
&#xD;
          -  Ulcer area between 0,5 and 16 cm2&#xD;
&#xD;
          -  If there is more than one ulcer or bilateral ulcers, the investigator shall choose the&#xD;
             one index ulcer to be treated (typically the largest one). The other ulcers will&#xD;
             receive standard care and is not included in the study&#xD;
&#xD;
          -  Ulcer type: University of Texas grade IA.&#xD;
&#xD;
          -  Evidence of adequate arterial perfusion: Toe pressure reading of ≥ 30 mmHg or if toe&#xD;
             is missing, transcutaneous oxygen (TcPO2) of ≥ 30mmHg on the foot.&#xD;
&#xD;
          -  Patient foot is appropriately off loaded (contact cast, pneumatic walking cast)&#xD;
&#xD;
          -  Orthopaedic assessment has been completed to rule out a mechanical source of&#xD;
             ulceration&#xD;
&#xD;
          -  Relative wound area reduction less than 50% from week -3 to week 0 (pre-screening&#xD;
             period)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clear indication for surgery (vascular reconstruction or skin transplant)&#xD;
&#xD;
          -  Ulcer with exposed bone or tendon&#xD;
&#xD;
          -  Bone involvement (probe to bone or x-ray)&#xD;
&#xD;
          -  Patients with 3 ulcers or more at the foot investigated&#xD;
&#xD;
          -  Osteomyelitis&#xD;
&#xD;
          -  Clinical signs of infections&#xD;
&#xD;
          -  Necrosis in the wound (one week into the screening period).&#xD;
&#xD;
          -  Patients with known MRSA&#xD;
&#xD;
          -  Malnutrition. Albumin &lt; 2,5g/dl&#xD;
&#xD;
          -  Ulcers resulting from electrical, chemical, radiation burns&#xD;
&#xD;
          -  HbA1c &gt; 12%&#xD;
&#xD;
          -  Male: Hb &lt; 8 mmol/l (12,9 g/dlFemale: Hb &lt; 7 mmol/l (11,3 g/dl)&#xD;
&#xD;
          -  Platelet count &lt;140 *109/l&#xD;
&#xD;
          -  Pregnancy and fertile women not practicing sufficient birth control&#xD;
&#xD;
          -  Fertile women having a positive pregnancy test week 0 Lactating women&#xD;
&#xD;
          -  Patients on haemodialysis&#xD;
&#xD;
          -  History of peripheral vascular repair within 4 weeks prior to study enrollment&#xD;
&#xD;
          -  Bleeding disorders, haemophilia, sickle cell disease, thrombocytopenia, and leukaemia&#xD;
             or blood dyscrasias&#xD;
&#xD;
          -  Current treatment for malignancy or neoplastic disease or collagen vascular disease&#xD;
&#xD;
          -  Highly communicable disease or diseases that may limit follow - up (e.g.&#xD;
             immunocompromised conditions, hepatitis, active tuberculosis)&#xD;
&#xD;
          -  Patient has inadequate venous access to draw blood&#xD;
&#xD;
          -  History of alcohol or drug abuse within the last year prior to randomization&#xD;
&#xD;
          -  Patient known to have psychological, developmental, physical, emotional or social&#xD;
             dis-order or other ailments that may interfere with the study requirements&#xD;
&#xD;
          -  Patients enrolled in an other clinical trial for wound treatment within 30 days prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Non-compliance in the screening period&#xD;
&#xD;
          -  Patients who have received growth factor therapy e.g. becaplermin within 7 days prior&#xD;
             to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Ruge</last_name>
    <role>Study Director</role>
    <affiliation>Vivostat</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woundhealing Centre Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Klinik Bad Mergentheim GmbH</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum Mathias Hospital</name>
      <address>
        <city>Rheine</city>
        <zip>48431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes/ Endokrin sektion</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <last_update_submitted>October 7, 2011</last_update_submitted>
  <last_update_submitted_qc>October 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complete healing of chronic diabetic foot ulcers</keyword>
  <keyword>Platelet Rich Fibrin</keyword>
  <keyword>Vivostat</keyword>
  <keyword>Growth factor treatment</keyword>
  <keyword>Treatment of chronic diabetic foot ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

